ClinicalTrials.gg
RecruitingNCT06375187KUNLUN-001Updated Dec 11, 2025

A Study of GC203 TIL in Advanced Malignant Solid Tumors

A Phase 1 interventional study of Engineering Tumor Infiltrating Lymphocytes in Solid Tumor, Gynecologic Cancer and Breast Cancer, sponsored by Shanghai Juncell Therapeutics. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by Shanghai Juncell Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,928 studies in Breast Neoplasms with a site in China — 866 open to participants now, 1,064 under way, 210 of them phase 3. Breast Neoplasms · China.

Planned enrollment
1,443rd of 1,519
18 · median 120
Started
2024
with 221 others
Phase 1
171 of 1,928
61 open now
Primary completion
2026-11
later than 499 of 1,063 live
Registered
1,293rd of 1,928
by date

Among the 1,928 studies in Breast Neoplasms with a site in China, this one is the 1,443rd largest by planned enrollment of the 1,519 interventional ones that give a count, is one of 222 that started in 2024, is one of 171 in phase 1, reaches primary completion later than 499 of the 1,063 other live ones, and was the 1,293rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

866 of the 1,928 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

861 more — sign in →

All 866 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,928 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors

03

Conditions studied

  • Solid Tumor
  • Gynecologic Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Lung Cancer

Keywords

  • Adoptive cell therapy
  • Tumor Infiltrating Lymphocytes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. In the opinion of the Investigator, patients must be able to sign the ICF and complete all study-required procedures.

    2. Patients must be ≥18 and ≤75 years of age at the time of consent. 3. Patients with advanced solid tumors with clear pathological diagnosis have failed standard therapy (standard therapy is defined as existing guidelines and consensus recommended therapy [including but not limited to chemotherapeutic therapy, radiotherapy, mutation-targeted therapy, immunotherapy, and surgery]) , including but not limited to gynecological tumors (ovarian cancer, endometrial cancer, cervical cancer), breast cancer, gastrointestinal Cancer, lung cancer.

    4. Patients have feasible tissue areas for tumor resection/puncture to generate GC203 TIL, the total volume of the tissue > 400mm3, and the lesion has not received local treatment (such as radiotherapy, radiofrequency therapy, oncolytic virus, etc.) or has progressed after local treatment; 5. At least one measurable target lesion before preconditioning, as defined by RECIST1.1.

    6. Patients must have an (ECOG) performance status of 0 or 1.

    7. Patients must have an estimated of ≥3 months. 8. Patients must have the following hematologic parameters, Coagulation functions and hepatic and renal function:

    • (ANC)≥1.0×10\^9/L;
    • Absolute Lymphocyte Count(ALC)≥0.5×10\^9/L;
    • ≥80×10\^9/L;
    • (INR)≤1.5×;
    • Activated Partial Thromboplastin Time(APTT)≤1.5×ULN;
    • Serum Creatinine (Scr)≤1.5mg/dL (or 132.6μmol/L) or ≥60mL/min
    • Urinalysis: urine protein less than 2+, or 24-hour urine protein \<1g;
    • (AST/SGOT) ≤3×ULN;
    • Alanine aminotransferase (ALT/SGPT) ≤3×ULN;
    • Total (TBIL)≤1.5×ULN; 9. Women of (WCBP), must have a negative serum pregnancy test prior to treatment. All sexually active WCBP and all sexually active male subjects must agree to use effective methods of throughout the study.

      10. Patients must have no for surgery or . 11. Patients have good compliance and be able to adhere to research access plans and other protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Participate in clinical trials of other drugs or biologic therapies within 4 weeks before enrollment;
  2. Participants who have had a history of allogeneic T cell therapy; gene engineering autologous cell therapy within 1 years.
  3. Patients who have received systemic antitumor therapy within 4 weeks.
  4. Patients who have had another primary within the previous 5 years
  5. Patients who have received a live or attenuated vaccination within 28 days prior to the start of treatment
  6. Patients with a history of to any component of the study drugs
  7. Patients who are pregnant or breastfeeding.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Treatment Arm

    Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL)

    Biological: Engineering Tumor Infiltrating Lymphocytes

Interventions

  • A tumor sample is resected from each participant and cultured ex vivo to generate the engineered tumor infiltrating lymphocytes. After lymphodepletion, patients are infused GC203 TIL followed low-dose PD-1 antibody.

    Also known as: GC203 TIL

06

What researchers measure

Primary outcomes

  1. Maximal Tolerance Dose

    Time frame: Up to Day 28

  2. Dose Limiting Toxicity

    Time frame: Up to Day 28

  3. Adverse Events

    Time frame: Maximum 360 days

Secondary outcomes

  1. Objective Response Rate

    Evaluate the efficacy endpoints of ORR by the investigator with RECIST v1.1 and iRECIST

    Time frame: Every 6 weeks for 12 months

  2. Duration of Response

    Evaluate the efficacy endpoints of DoR by the investigator with RECIST v1.1 and iRECIST

    Time frame: Every 6 weeks for 12 months

  3. Disease Control Rate

    Evaluate the efficacy endpoints of DCR by the investigator with RECIST v1.1 and iRECIST

    Time frame: Every 6 weeks for 12 months

  4. Progression-Free Survival

    Evaluate the efficacy endpoints of PFS by the investigator with RECIST v1.1 and iRECIST

    Time frame: Every 6 weeks for 12 months

  5. Overall Survival

    Evaluate the efficacy endpoints of OS by the investigator with RECIST v1.1 and iRECIST

    Time frame: Every 6 weeks for 12 months

  6. Quality of Life Assessment

    Evaluate with EORTC QLQ-C30

    Time frame: Every 6 weeks for 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Nov 2026, 29 months after the start.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 29 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2024
First posted
Apr 19, 2024
StartActual
May 29, 2024
Primary completionEst.
Nov 1, 2026
CompletionEst.
May 1, 2027
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06375187
Lead sponsor
Shanghai Juncell Therapeutics
Responsible party
Sponsor
First posted
Apr 19, 2024
Start date
May 29, 2024
Primary completion
Nov 1, 2026 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Dec 11, 2025

Study contacts

Huajun Jin, PhD
Contact
clinicaltrials@juncell.com
+8621-69110327
Xiaohua Wu, Phd
Contact
Wu.xh@fudan.edu.cn
+862165675209

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GC203

Start the discussion